CD274 and lung cancer: The Food and Drug Administration approved the antiprogrammed cell death‐1 (PD‐1) antibody, pembrolizumab in combination with chemotherapy, as a first‐line therapy for metastatic non‐small cell lung cancer (NSCLC), irrespective of programmed cell death ligand‐1 (PD‐L1) status in July 2018 based on the results reported by the Keynote‐1892 and Keynote‐407 studies.3